urea/脳卒中

FIELD OF THE INVENTION This invention relates to certain novel thrombin receptor antagonists, their synthesis and their use for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic

The invention relates to amide and urea derivatives of the formula I in which R.sup.1 is 3-indolyl which is unsubstituted or mono- or disubstituted by A, AO, OH, Hal, CN, NO.sub.2, NH.sub.2, NHA, NA.sub.2, COA, CONH.sub.2, CONHA, CONA.sub.2, CH.sub.2 OH, CH.sub.2 OA, CH.sub.2 NH.sub.2, CH.sub.2 NHA,

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to

FIELD OF THE INVENTION This invention relates to a new class of compounds, which are potent and highly selective inhibitors of factor Xa, both isolated and when assembled in a complex with other proteins. In another aspect the invention relates to a new class of compounds, their pharmaceutically

FIELD OF THE INVENTION This invention relates to urea and thiourea derivatives, which are useful for the inhibiting of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT), and to medical use of such derivatives. BACKGROUND OF THE INVENTION Inhibition of the enzyme nicotinamide

SUMMARY OF THE INVENTION The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha..sub.4.beta..sub.1), the .alpha.4.beta.7 integrin (LPAM-1 and .alpha..sub.4.beta..sub.p), and/or the .alpha.9.beta.1 integrin, thereby blocking the

FIELD OF THE INVENTION The present invention concerns novel urea and thiourea derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by urea or thiourea derivatives. The

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

FIELD OF THE INVENTION The present invention relates to image processing units and optical sensor devices for obtaining biophysical, biochemical, physiological and vital sign information from an array of photodetectors or from video image data including stored video image data. BACKGROUND OF THE

PRIORITY This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050904 titled COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME filed on Feb. 3, 2013 Published with WIPO Publication # WO/2013/167996, which further claims priority to

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1836/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050907 filed on 3 Feb. 2013; the entire disclosure of which is relied on for all purposes and is incorporated into this